Abstract: Melanoma accounts for only a small portion of skin cancer but it is associated with high mortality. Melanoma serum biomarkers that may aid early diagnosis or guide therapy are needed clinically. However, studies of serum biomarkers have often been hampered by the serum interference that causes false readouts in immunological tests. Here we show that, after using a special buffer to eliminate the serum interference, IL-8 and cathepsin B levels were significantly elevated in melanoma patients (p < 0.05). More importantly, the combination of IL-8 and cathepsin B were also studied as a prognosis marker for melanoma mortality. Our study provides a novel approach to examine serum biomarkers.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Zhang, H.; Fu, T.; McGettigan, S.; Kumar, S.; Liu, S.; Speicher, D.; Schuchter, L.; Xu, X. IL8 and Cathepsin B as Melanoma Serum Biomarkers. Int. J. Mol. Sci. 2011, 12, 1505-1518.
Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X. IL8 and Cathepsin B as Melanoma Serum Biomarkers. International Journal of Molecular Sciences. 2011; 12(3):1505-1518.
Zhang, Hongtao; Fu, Ting; McGettigan, Suzanne; Kumar, Suresh; Liu, Shujing; Speicher, David; Schuchter, Lynn; Xu, Xiaowei. 2011. "IL8 and Cathepsin B as Melanoma Serum Biomarkers." Int. J. Mol. Sci. 12, no. 3: 1505-1518.